Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 17.1%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 575,500 shares, a decline of 17.1% from the February 28th total of 694,600 shares. Approximately 3.5% of the company’s stock are short sold. Based on an average daily trading volume, of 3,880,000 shares, the short-interest ratio is currently 0.1 days.

Xilio Therapeutics Stock Performance

XLO opened at $0.73 on Thursday. The company has a market capitalization of $37.86 million, a P/E ratio of -0.43 and a beta of -0.38. The company has a 50-day moving average of $0.85 and a 200-day moving average of $0.93. Xilio Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.72 million for the quarter, compared to analyst estimates of $2.26 million. As a group, sell-side analysts expect that Xilio Therapeutics will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xilio Therapeutics

Several large investors have recently added to or reduced their stakes in XLO. Gilead Sciences Inc. acquired a new stake in shares of Xilio Therapeutics during the fourth quarter worth $8,696,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Xilio Therapeutics during the 4th quarter valued at about $1,416,000. Geode Capital Management LLC raised its stake in Xilio Therapeutics by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 358,422 shares of the company’s stock worth $342,000 after acquiring an additional 20,230 shares during the period. Balyasny Asset Management L.P. raised its stake in Xilio Therapeutics by 26.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock worth $328,000 after acquiring an additional 70,744 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 11.4% in the fourth quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock worth $283,000 after acquiring an additional 30,317 shares during the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.